Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: GlobeNewswire
– IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children six years of age and above – – First-ever authorised treatment option in Great Britain (England, Scotland and Wales) for these rare genetic diseases of obesity – – IMCIVREE selected as ‘highly specialised technology’ and scheduled for review by National Institute for Health and Care Excellence (NICE) in December 2021 – BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to IMCIVREE® (setmelanotide) for the treatment of obesit
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals Announces New Employment Inducement GrantsGlobeNewswire
- Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.MarketBeat
- Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock FinancingGlobeNewswire
RYTM
Earnings
- 2/22/24 - In-Line
RYTM
Sec Filings
- 4/17/24 - Form SC
- 4/16/24 - Form 4
- 4/16/24 - Form 8-K
- RYTM's page on the SEC website